Tango Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $265.00K, a 39.77% decline year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $193.00K, a 19200.00% increase year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $324.00K, a 3500.00% increase year-over-year.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $440.00K.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.06M, a 2545.00% increase from fiscal 2020.
- Tango Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $40.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-03-31 | $265.00K 10-Q · filed 2022-11-10 | |
| 2021-12-31 | $1.06M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $193.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $324.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $440.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $40.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $9.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |